vTv Therapeutics (NASDAQ:VTVT) Stock Rating Upgraded by BTIG Research

vTv Therapeutics (NASDAQ:VTVT) was upgraded by BTIG Research to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other brokerages also recently commented on VTVT. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of vTv Therapeutics in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.00.

vTv Therapeutics Price Performance

Shares of NASDAQ VTVT opened at $32.24 on Tuesday. The company has a 50-day moving average price of $23.51 and a 200-day moving average price of $19.10. The stock has a market capitalization of $126.96 million, a P/E ratio of -10.33 and a beta of 0.66. vTv Therapeutics has a 1 year low of $13.15 and a 1 year high of $33.16.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. Connective Capital Management LLC purchased a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 9,377 shares of the biotechnology company’s stock, valued at approximately $162,000. Connective Capital Management LLC owned about 0.29% of vTv Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.